In This Article:
HeraMED (ASX:HMD) Full Year 2024 Results
Key Financial Results
-
Revenue: AU$364.3k (down 38% from FY 2023).
-
Net loss: AU$5.49m (loss narrowed by 17% from FY 2023).
-
AU$1.03 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
HeraMED shares are down 15% from a week ago.
Risk Analysis
You still need to take note of risks, for example - HeraMED has 6 warning signs (and 5 which make us uncomfortable) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.